The weight loss drugs Ozempic and Wegovy may be beneficial for people struggling with alcohol addiction, a study published ...

Not only is Wegovy extremely effective (people lose about 15% of their body weight in a year), it also appears to have many ...

周三，诺和诺德公布了三季度业绩，减肥药Wegovy当季销售额超出预期。这一消息让投资者们松了一口气，因为其竞争对手礼来上周报告的减肥药销量令人失望。受此影响，美股诺和诺德盘前大涨5%。今年以来，由于减肥药火爆，诺和诺德股价一路走高，并于6月25日触及 ...

It’s hard to remember a time before Ozempic, Wegovy, and other injectable drugs referred to as GLP-1 receptor agonists (that ...

诺和诺德凭借其前瞻性的市场策略与卓越的产品表现，成功地在减肥药市场中脱颖而出。Wegovy的成功不仅是公司自身的辉煌，更是整个减肥药市场回暖的重要信号。随着行业的不断发展，如何抓住这一波减肥药热潮，成为各大制药公司的关注焦点。未来的减肥药市场必将在技术进步和消费升级的双重推动下，迎来更为广阔的发展前景。

The blockbuster drugs Ozempic and Wegovy may help people cut back on drinking, new research published Wednesday in JAMA ...

A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at ...

丹麦制药公司诺和诺德公司报告称，其肥胖药物Wegovy在第三季度的销售强劲，超过了分析师的预期。销售额达到173亿丹麦克朗（约合24.9亿美元），比上一季度增长48%，高于预期的159亿克朗。

生产“减肥神药”Wegovy的丹麦药厂诺和诺德 (Novo Nordisk)第三季盈利273.01亿丹麦克朗 ...

Ro details dietary choices that may help Wegovy's capacity to regulate appetite and foster a healthier weight as well as ...

【ITBEAR】诺和诺德三季度财报亮相，减肥药Wegovy销售额超预期，引领业绩增长。 丹麦制药巨头诺和诺德近日发布2024年第三季度财报，显示公司营收与净利润均实现增长，其中明星减肥药Wegovy的销售额更是超出市场预期，成为推动业绩增长的重要力量 ...

诺和诺德第三季度净利润为273.01亿丹麦克朗，同比增长21%，高于市场预期的267亿丹麦克朗。Wegovy收入增长79%，达到173亿丹麦克朗，高于预期156亿丹麦克朗，其中美国的销售额增长了约50%。